Determination of priority and contribution rate of genes involved in breast stromal cells cancer on the basis of microarray analysis by mathematical modeling

Breast cancer is one of the prevailing types of cancers and main cause of death in women suffering from cancer. Determination of factors involved in the development of this disease is one of the main challenges of modern medical society. Genetic factors are effective factors in generation of breast cancer and the role of some genes in this disease were denoted in some medical reports. Regarding restriction of valid information on changes in genes expression in this type of cancer for mathematical modeling، in this study، genes expression information that were needed for modeling was obtained from the NCBI website.

In this descriptive study، the dataset of gene expression derived from microarray analysis of 5 healthy individual and 28 patients with breast stromal cell cancer was gathered from NCBI website. Then، expression of 22277 genes related to this type of cancer was modeled. In this model، each gene was considered as a player in transferable utility (TU) game and contribution rate of each gene in this type of cancer was calculated. Finally 200 genes with high contribution rate were chosen and ranked.

The results of this research indicate that more than 200 genes have high contribution rate in incidence of this type of cancer. However، changes in DDR1، SLC23A2 and PADI2 genes expression have the highest contribution rate comapred with other genes in breast stromal cells cancer. ‍

It seems that changes in expression of many genes are participating in this type of cancer. In support of our findings، the role of expression change in DDR1 and PADI2 genes in this type of cancer were shown experimentally in previous studies. But، this research is unique for assortment of genes with expression change in breast cancer. This ranking of gene expression has decision supporting value in the diagnosis and treatment of cancer. Final decision about accuracy of our classification is certainly subject to confirmation by future analytical experiments on expression of genes that participate in breast cancer.